assumpt coverag
capston turbin corpor cpst buy pt expect multipl type custom instal back-up power
assum coverag buy rate price analyst tate sullivan cfa full summari
eurodri ltd edri buy pt expect rebound rate second half assum coverag buy
rate price analyst tate sullivan cfa full summari
eurosea ltd esea buy pt expect share start anticip sector rebound assum coverag
buy rate price analyst tate sullivan cfa full summari
inc buy pt result guidanc weak preview lower pt record defer revenu
mynd analyt inc mynd buy pt telebehavior health could futur new partnership announc
merger-spinoff emmau repres upsid analyst anthoni vendetti full summari
agil inc agrx buy pt start clock twirla resubmit nda accept review pdufa
inc buy pt growth continu enhanc astero aquisit bring
corpor event call maxim salesperson inform
zosano pharma corpor zsan cover vendetti ndr nyc ceo john walker cfo greg kitchen
maxim group alzheim diseas confer nyc ntrp inmb sava alpha pa aztherapi
host mccarthi wed jun
maxim group industri confer nyc evsi gpvrf mg
sgbx host sullivan thu jun
inc cover ndr boston cfo golder vice-president
cover chokshi ndr boston ceo jeff rosica thu may
pareteum corpor cover klee ndr chicago presid deni mccarthi corpor
develop investor relat michael bloom mon jun
pareteum corpor cover klee ndr dalla presid deni mccarthi corpor
develop investor relat michael bloom tue jun
annual silicon valley bu tour host chokshi tue
result guidanc weak preview lower pt
april quarter low-end guidanc preview weak renew
larger factor weak product revenu
exclud year-ago strong ela perform renew improv
guidanc low-end prior rang back record defer revenu
build acceler increment add cloud data servic also
impli product revenu y/i growth acceler eas year-ago
reiter buy rate due differenti hybrid cloud stori though slightli
price target
april quarter low-end guidanc preview weak renew
larger factor weak product revenu last night report april
revenu y/i y/i exclud fx low-
end guidanc rang in-lin reduc estim preview
consensu product revenu y/i flat exclud fx
estim consensu softwar entitl
mainten in-lin consensu estim hardwar
mainten servic estim
consensu manag note weak product revenu rel
consensu result weak macroeconom environ within emea
y/i y/i excl fx notabl broad-bas larg enterpris
weak impact result abat evidenc us commerci
asia revenu acceler apiec note weak emea result also
consist earn call commentari super micro smci buy
weak hardwar mainten result result weak execut manag
believ self-inflict rather macro competit dynam driven
compani alreadi taken correct action product gm impress
y/i manag note would even without
enterpris licens agreement ela sign due improv sale forc disciplin
growth software-onli product opex flat y/i result flat net
incom ep growth rose due continu aggress share buy back
vs past quarter
exclud year-ago strong ela perform renew improv revenu
guidanc repres wider rang usual
midpoint repres y/i howev exclud ela recogn
juli manag expect ela within juli
 well fx headwind manag note overal revenu
guidanc impli revenu y/i apples-to-appl basi triangul
midpoint guidanc also impli product revenu remain flattish y/i also
expect hardwar mainten servic revenu increas back
least flat y/i level juli quarter given correct action taken within april
 non-gaap ep guidanc impli non-gaap om
y/i larg result lap year-ago quarter near gm
guidanc low-end prior rang back record defer revenu
build acceler increment add cloud data servic also
impli product revenu y/i growth acceler eas year-ago growth
rate manag expect revenu low-end mid-
singl digit guidanc rang interpret mean prior
estim y/i growth consensu given jul guidanc
compani expect normal season wherea year-ago
period normal season play impli acceler y/i growth
progress expect acceler partial driven better execut
renew hardwar support impli record q/q increas defer
revenu led record defer revenu st defer revenu
also note short-term defer revenu built faster long-term
defer revenu impli effect instal base repres also
acceler believ part acceler acceler increment cloud
data servic within april increment lead
rate month april manag also provid guidanc non-
gm vs om vs
low-end guidanc rang arriv ep estim reduc
reiter buy rate due differenti hybrid cloud stori though reduc
price target despit weak april result believ
strong defer revenu growth suggest remain secular growth stori
fortifi prior channel check indic ntap lead cloud servic
provid prove sustain multilay technolog differenti extern
storag array rel emc fujitsu enabl on-going on-premis
storag market share gain evid custom becom commit
util pay premium price softwar technolog reduc
guidanc lead us lower revenu estim
respect ep estim result
price target reduc form base multipl
take account acquisit add back net cash-per-share discount
back two year weight cost capit wacc
click full note
telebehavior health could futur new
partnership announc merger-spinoff emmau
mynd process merger-spinoff emmau life scienc
emmau subsequ transact
monday may mynd report revenu gross
margin expect in-line ep
mynd announc partnership compass network may
offer telebehavior health servic arcadian subsidiari
april compani plan regain complianc list
accept
bottom line mynd report revenu gross margin
expect in-line ep mainli due lower expect sale
peer system howev optimist mynd potenti telemedicin
network predict analyt market specif expans
product servic offer arcadian telepsychiatri mynd wholli own
subsidiari exampl may mynd announc partnership
compass network privat offer telebehavior health servic arcadian
provid network upstat new york partnership allow telehealth solut
varieti organ includ nurs home primari care pharmaci behavior
health agenc visit nurs servic opinion mynd well-posit
drive improv care lower cost mental health patient telemedicin
network predict analyt arcadian subsidiari
flat y/i slightli estim consensu
neurometr revenu y/i estim
telepsychiatri revenu y/i slightli estim
gross margin y/i estim
consensu net loss per share rel in-line
estim consensu march mynd
cash equival debt
reduc estim due result expect reduc
sep revenu estim
respect also expect higher oper
expens therefor widen ep loss
per share estim
compel valuat mynd trade ev/revenu multipl
forecast peer averag deriv price target employ
dcf analysi discount rate perpetu growth rate
impli share trade revenu estim believ justifi
due signific opportun mental health telemedicin
click full note
expect share start anticip sector rebound
 assum coverag buy rate price
esea recent vessel employ chart indic nine
compani ship contract end four
contract averag declin rate
base part previous disclos inform potenti
challeng secur new contract first half assum
coverag estim previous estim
forecast ebitda million prior year
rebound base better contract environ estim
growth
esea plan releas result may
assum coverag buy rate price target
previous price target base ebitda forecast
million prior price target base previous
publish ebitda forecast million
earn schedul releas forecast ebitda
declin q/q base aforement pressur contract price
anticip q/q decreas ebitda esea indic last earn
present current idl ship need contract price start improv
sometim forecast ebitda start rebound anoth q/q
decreas estim million q/q
esea end million asset million debt interest
expens million esea million proce sell
vessel unrestrict cash million end compar restrict
cash million base review esea commit build
acquir addit ship
assum coverag buy rate price target share current trade
ev/ebitda multipl ebitda forecast million new
price target base ebitda forecast prior price target
base previous publish ebitda forecast million
appli slightli lower multipl compar peer group averag ev/ebitda
multipl base part meaning declin contract price first half
click full note
expect rebound rate second half
assum coverag buy rate price
maintain previous publish estim revenu million
ebitda million ahead edri next quarterli earn report
compani plan releas market close today
edri complet spin-off eurosea esea buy may
revenu ebitda forecast incorpor declin
result base part lower ship rate result less demand
china coal
base edri last present compani seven ship
averag age year six seven ship fulli contract
forecast higher ebitda second half ship activ
better rate first half expect revenu declin
million million second half due less demand
coal import china lower grain harvest potenti neg impact
global ship activ on-going china-u trade disput forecast
rebound demand edri ship second half higher charter
rate revenu million first half year
edri end million asset million debt
million prefer equiti edri current debt million long-term debt
million three credit facil secur first prioriti mortgag
vessel edri cash flow oper million compani
spent million vessel million prefer stock pay dividend
either in-kind cash compani option convert per
share prefer dividend goe stock rise per share
prefer stock subject mandatori convers two year stock
price per share
assum coverag buy rate price target share current trade
ev/ebitda multipl ebitda forecast million
price target base ebitda forecast million appli
lower multipl compar peer group averag ev/ebitda multipl
ebitda consensu forecast base part edri small fleet compar
ship compani
click full note
expect multipl type custom instal back-up
power assum coverag buy rate
assum coverag cpst buy rate price target cpst
announc earlier week order energi custom wyom
two new patent relat use hydrogen liquid fuel gener
cpst rent sell equip call microturbin among product
gener electr natur ga propan liquid fuel
includ diesel kerosen
april cpst announc preliminari result quarter
end march includ revenu million y/i revenu
quarter end decemb declin y/i
cpst current plan announc full result fiscal year end
march june
forecast revenu million previous print
estim million base cpst potenti growth multipl end
market includ data center hospit larg offic build
believ cpst abl sell microturbin new custom
slightli increas expens estim fund long-term growth
opportun forecast neg ebitda million wider
previous publish million forecast
cpst end march million cash secur new debt
financ februari end cpst million debt
balanc sheet versu million cash includ million restrict
cash april cpst announc end cash million
februari cpst secur three-year term note goldman sach gs
rate million replac million revolv credit facil term
debt annual interest rate
believ cpst rent microturbin cpst alloc
microturbin new long-term rental program potenti custom rent
microturbin includ oil ga custom need electr produc oil
natur ga remot well locat larg build construct may also
need rent microturbin sourc electr perman connect
electr grid addit opportun rent microturbin believ mani
custom continu instal back-up sourc electr reduc relianc
local util tri cut util bill
assum coverag buy rate price target cpst current ev/
revenu multipl price target base ev/revenu multipl
revenu forecast comparison aggreko plc aggk rate
tecogen tgen buy share current trade consensu revenu
estim respect gener believ compani exhibit higher revenu
growth cost growth industri long-term growth potenti trade
premium multipl revenu support note forecast cpst increas
ebitda million neg ebitda million base
oper leverag demand back-up power system growth cpst
click full note
growth continu enhanc astero
biolif report revenu y/i
sequenti gross margin biolif also report net
profit quarter end period cash note
includ revenu astero acquisit complet
distributor revenu came largest segment sale
y/i regen medicin rm gener y/i
main reason modest y/i growth
significantli reduc rm sale volum major rm custom though
volum custom rebound far expect rm
revenu return higher growth addit initi revenu relat
astero acquisit thawstar transact close april
contribut revenu growth well
new custom ad biolif ad new custom
direct rm compani addit compani receiv new fda
conclus biolif continu execut strategi expand posit
key tangenti player cell therapi space expect revenu growth
continu particularli thawstar order come combin
cell media ship thaw thawstar biolif essenti
one-stop shop cell gene therapi space
guidanc reiter manag reiter guidanc includ
astero acquisit sale expect revenu gross margin
oper expens full-year profit
astero acquisit astero acquisit complet
up-front cash payment acquisit bring automat thaw product
line call thawstar could reduc risk contamin overh
associ tradit water bath thaw order thawstar come
includ exist cell gene therapi custom contribut
grow custom base biolif custom ad new
regen medicin custom recal new cell gene
therapi product gain approv could potenti gener recur
annual revenu biolif media embed uniqu custom
applic includ dozen car-t includ gener car-t
compani custom late-stag develop could drive sale
growth expect approv includ kiadi kd nr
 hold lentiglobin
click full note
start clock twirla resubmit nda accept
agil announc fda accept review nda resubmiss
twirla compani low-dos combin hormon contracept patch
resubmiss address issu complet respons
letter class respons review pdufa novemb
issu relat safeti efficaci
view key keep mind issu relat qualiti
control adhes test method manufactur process third-parti
manufactur observ inspect question adhes
properti twirla potenti relationship secur trial result
agil believ issu address includ result
wear studi announc februari demonstr non-inferior issu
adhes continu safeti
remind twirla trial phase enrol women
includ third phase trial secur enrol combin
wear studi address issu relat agil
box check thu believ probabl twirla
gain approv favor agil
twirla low-dos weekli chc transderm patch contain combin
estrogen ethinyl estradiol progestin levonorgestrel made worn
buttock abdomen upper torso seven day straight chang
week three consecut week one patch-fre week time
woman withdraw bleed use correctli twirla effect
rate posit safeti profil agil incorpor proprietari skinfus
adhes technolog patch design twirla subject three phase
trial recent compar adhes wear studi latter
request fda part twirla met primari endpoint non-
inferior xulan fda consid accept adhes patch
contracept nda resubmit accept review
pdufa prescript drug user fee act goal date
combin hormon contracept chc market gener revenu
per year twirla repres first low-dos patch option xulan twirla may
abl provid safer black box low-dos ethinyl estradiol vs patch
altern xulan view low-dos hormon line women prefer
choos chc could attract option drive market adopt twirla
approv
adhesion-wear studi note adhes wear studi request
part data announc februari two-week
studi random crossov wear studi healthi women less
subject wore twirla xulan patch first week
switch patch second week adhes non-inferior establish
adhes studi demonstr twirla mean differ upper
confid limit statist non-inferior xulan reach
upper confid limit mean differ less data
combin respons relat use support nda
click full note
maxim analyst coverag univers
